anthralin/erythema

The effect of tar on anthralin-induced erythema was epicutaneously tested in ten patients. 3%, 5%, or 10% crude coal tar or coal tar solution was added to vaseline containing anthralin. A 5% or 10% tar preparation significantly suppressed the anthralin erythema induced by 0.5 to 1.0% anthralin

A comparative study on psoriatic patients and healthy volunteers demonstrated that short-term treatment with Anthralin shows significantly less side-effects on healthy skin than long-term therapy. We could also prove that the oxidation products Chrysazin and Bianthron do not cause any irritations,

Irritation and staining caused by equi-irritant doses of dithranol (anthralin) and 10-butyryl dithranol (butantrone) were observed for one week after a single 24-hour exposure under occlusion. The test chambers were applied on the uninvolved dorsal skin of 11 psoriasis patients. The estimates of

Anthralin has been applied in low and high concentrations with and without UV-irradiation in the treatment of psoriasis (Schauder & Mahrle, 1982a,b). We have studied the relationship between the sensitivity to anthralin and UV-irradiation which might possibly help us to give a more individually

Anthralin is a safe, effective treatment for psoriasis, but its efficacy is hampered by the side-effects of irritation and staining of the uninvolved skin. To avoid burning, it is customary to start at low concentrations and increase every 48-72 h until the therapeutically effective concentration is

In 20 volunteers, we were able to demonstrate experimentally that side-effects of anthralin application on healthy skin development of erythema and pigmentation, can be significantly reduced in a short contact therapy, in comparison to a longterm treatment. The oxydation products

1 The effect of topical arachidonic acid on anthralin inflammation was studied using sequential measurements of erythema (reflectance photometry) and oedema (calipers). 2 Topical arachidonic acid in concentrations which produced a small short-lived inflammatory response greatly augmented the initial

The effect of prostaglandin inhibition, using topical indomethacin, on anthralin inflammation was studied. Indomethacin gel and gel base were applied to opposite flexor forearm skin sites of 11 volunteers for 2 h and then washed off. Anthralin and UVB were then applied to the gel-treated skin and

The effect of topical clobetasol propionate and a 1% topical indomethacin gel which could inhibit UV erythema was measured on anthralin inflammation by change in skin-fold thickness and erythema. The time course of the inflammatory oedema and erythema were different, as was their response to the

Anthralin cream 0.5% to 1.0% was used to treat 68 patients with severe alopecia areata. Therapy was relatively well tolerated, although all patients experienced pruritus and local erythema and scaling. Cosmetic response was seen in 17 (25%) of the patients, and was maintained during therapy in 12

Anthralin erythema dose-response curves were drawn for thirty adult patients of various skin types who had chronic plaque psoriasis. A small statistically significant difference was observed between the curves for skin types I and IV but this was not thought to be sufficient to account for the

Recent trends in psoriasis therapy favor using lower-strength anthralins. To assess the effectiveness of a low concentration (0.01%) v a mid concentration (0.1%) of anthralin, combined with UV-B therapy, a prospective double-blind study was undertaken. Nine patients with chronic plaque-type